Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 12/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 12/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 12/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 12/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 12/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 12/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15746126 | 0.87 | PSEN1 (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL15746119 | 0.84 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL9224953 | 0.84 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL15746123 | 0.77 | PSEN1 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14636126 | 0.72 | PSEN1 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2228998 | 0.72 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2278671 | 0.69 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL957309 | 0.69 | PSEN1 (0.77) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL958811 | 0.69 | CYP2C9 (0.75) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL954828 | 0.69 | CYP2C9 (0.75) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115143-B2 | Substituted indole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115143-B2 | Substituted indole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140148450-A1 | NOVEL SUBSTITUTED INDOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-29 | — | — | US | disclosed |
| US-20140148450-A1 | NOVEL SUBSTITUTED INDOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148450-A1 | NOVEL SUBSTITUTED INDOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APP | PSEN1 6/4885PSEN2 8/4885APH1B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.